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Abstract
Metronomic chemotherapy, combined with targeted antiangiogenic drugs, has demonstrated significant anticancer
efficacy in various studies. Though, tumors do acquire resistance. Here, we have investigated the effect of prolonged
therapy with oral metronomic topotecan and pazopanib on tumor behavior in a neuroblastoma mouse xenograft
model. SK-N-BE(2) xenograft–bearing mice were treated with either of the following regimens (daily, orally): vehicle
(control), 150 mg/kg pazopanib, 1.0 mg/kg topotecan, and combination of topotecan and pazopanib. Planned dura-
tions of treatment for each regimen were 28, 56, and 80 days or until the end point, after which animals were sacri-
ficed.We found that only combination-treated animals survived until 80 days. Combination halted tumor growth for up
to 50 days, after which gradual growth was observed. Unlike single agents, all three durations of combination signif-
icantly lowered microvessel densities compared to the control. However, the tumors treated with the combination for
56 and 80 days had higher pericyte coverage compared to control and those treated for 28 days. The proliferative and
mitotic indices of combination-treated tumors were higher after 28 days of treatment and comparable after 56 days
and 80 days of treatment compared to control. Immunohistochemistry, Western blot, and real-time polymerase chain
reaction revealed that combination treatment increased the hypoxia and angiogenic expression. Immunohisto-
chemistry for Glut-1 and hexokinase II expression revealed a metabolic switch toward elevated glycolysis in the
combination-treated tumors. We conclude that prolonged combination therapy with metronomic topotecan and
pazopanib demonstrates sustained antiangiogenic activity but also incurs resistance potentially mediated by
elevated glycolysis.
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Introduction
There has been significant improvement in the survival rate among
pediatric cancer patients since the 1970s. In neuroblastoma, the 5-year
survival rate in children older than 1 year has increased from 35.3% in
1975 to 1978 to 64.8% in 1999 to 2002 [1]. However, the survival
rate in high-risk and recurrent neuroblastoma is still less than 40%
[2]. Drug resistance and dose-limiting toxicities are the major causes
of therapy failure in neuroblastoma; therefore, newer strategies like
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antiangiogenic therapy are being explored to enhance patient survival
with advanced neuroblastoma.
Antiangiogenic therapy has opened up new avenues and thera-
peutic options in the field of cancer chemotherapy. Among several
possible antiangiogenic strategies for pediatric cancers, low-dose
metronomic (LDM) chemotherapy and targeted antiangiogenic
agents have gained widespread attention [3,4]. Single agents have
demonstrated significant efficacy in various clinical and preclinical
settings [5,6]. Apart from antiangiogenesis, LDM chemotherapy acts
by several other mechanisms. Metronomic cyclophosphamide and
temozolomide have demonstrated antitumor immune stimulation
by inhibiting anti-immune T regulatory cells [7]. Topotecan has shown
an antitumor immune response of T cells in experimental gliomas
[8]. Vascular endothelial growth factor (VEGF) receptor inhibitors
sunitinib and sorefenib have also depleted T regulatory cells and
immunosuppressive myeloid-derived suppressor cells in renal cell
carcinoma (RCC) patients [9]. However, as single modalities LDM
therapy and antiangiogenic drugs have limited efficacy [4]. Enhanced
antitumor efficacies have been achieved by combining these two ther-
apies. A combination of LDM chemotherapy and a VEGF pathway
targeting antiangiogenic agent was first reported with metronomic vin-
blastine combined with anti–VEGF receptor 2 antibody DC101 in
neuroblastoma models [10]. More recent examples of such preclinical
investigations are LDM gemcitabine + sunitinib (pancreatic cancer),
LDMcyclophosphamide + thrombospondin (colon cancer), LDMcyclo-
phosphamide + endostar (lung cancer), and LDM topotecan + sunitinib
and bevacizumab (neuroblastoma) [11–14]. Such combinations have
demonstrated clinical efficacy in various adult and pediatric cancers
[15–21]. These examples also include the pediatric clinical trials con-
ducted by us, which involves the combination of metronomic chemo-
therapy with repositioned drug celecoxib, owing to the antiangiogenic
property of COX2 inhibitors [19,20].
Combining LDM topotecan and pazopanib has also demonstrated
significant advantage over either single agent alone in ovarian cancer
preclinical models [22,23]. Encouraged by these positive preclinical
observations, we investigated the efficacy of LDM topotecan and
pazopanib in mouse xenograft models of pediatric solid tumors [24].
Recently, this combination has shown advantage over the single agents
in colon cancer preclinical model [6]. Phase I trial of this combination
in gynecologic tumors has been conducted [25]. However, one dis-
advantage with the combination is that, even though it delayed tumor
growth, it failed to stop tumor growth in mice models of colon cancer,
ovarian cancer, and neuroblastoma even during the therapy. In our
neuroblastoma metastatic model, the combination therapy signifi-
cantly enhanced survival, but animals eventually succumbed to the
increasing tumor burden [24].
Our observations are in line with the report that metronomic
chemotherapy and antiangiogenic agents, even in combination with
chemotherapeutics, have not produced any significant enhancement
in overall survival [26–30]. Cancers either remain refractory to the
maintenance regimen of antiangiogenic therapy or show recurrence
or relapse. Therefore, there is a need to understand the changes in
tumor behavior in response to prolonged antiangiogenic therapy.
With this in mind, we have attempted to gain insight into the
dynamics of tumor response to LDM topotecan (TP) and pazopanib
(PZ) in our neuroblastoma mouse xenograft models. In the present
study, we evaluated the tumor behavior and phenotypic alterations
after treatment with LDM topotecan and pazopanib, over time,
in vivo using an MYCN-amplified cell line. Our results show that
the vascular supply initially reduced by the combination treat-
ment underwent a maturation process by developing a pericyte
coverage leading to continued growth and the potential to grow in
the hypoxic environment. Thus, tumors appear to adapt and acquire
renewed vigor.
Materials and Methods
Drugs and Reagents
Topotecan, (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-
1H-yrano [3′,4′:6,7] indolizino[1,2-b] quinoline-3,14 (4H ,12H)-dione
monohydrochloride, and pazopanib, (5-[[4-[(2,3-Dimethyl-2H-indazol-
6-yl)methyl amino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide,
were provided by GlaxoSmithKline (Collegeville, PA). SK-N-BE(2) cell
line was obtained from American Type Culture Collection (Manassas,
VA). The positive control tissue for hexokinase II (HK-II; glioblastoma)
was provided by Dr Gelareh Zadeh (The Hospital for Sick Children,
Toronto, Ontario). All other positive control tissues were provided
by the Division of Pathology, Department of Pediatric Laboratory
Medicine, The Hospital for Sick Children.
Tumor Treatment
The preclinical SK-N-BE(2) neuroblastoma xenograft model has
been previously described [24]. SK-N-BE(2) cells (1 × 106) were
implanted in the subcutaneous abdominal fat pad of non-obese diabetic
immunodeficient mice/severely combined immunodeficient (NOD/
SCID) mice (4-8 weeks), and when the tumors reached ≈0.5 cm in
diameter, mice were randomized into four treatment groups: control
(untreated), n = 4; PZ (150 mg of pazopanib), n = 8; TP (1.0 mg/kg
topotecan), n = 8; TP + PZ (combination of topotecan and pazopanib,
same doses as single agents), n = 12. Durations of treatment planned
for each regimen were 28, 56, and 80 days with end points for TP
and PZ not expected to go beyond 56 days, as per our observation
in the previous study [24]. Therefore, the mice in control, TP, PZ,
and TP + PZ were subrandomized into one, two, and three sub-
groups, respectively (n = 4 in each subgroup). In any subgroup, all
four mice were sacrificed on the same day, either on completion of
assigned duration of treatment or when one animal in that subgroup
reached the end point, whichever occurred first. The criteria for end
point termination were either tumor size exceeding 2.0 cm in diameter
or animals showing signs of morbidity.
Immunohistochemistry
Harvested tumors were either fixed in 10% formalin or rapidly
frozen in OCT media. Formalin-fixed and paraffin-embedded tissue
sections were cut at 5 to 7 μm, deparaffinized by xylene and ethanol,
and rehydrated in phosphate-buffered saline (PBS; #311-010-CL;
Wisent Bioproducts, St Bruno, Quebec, Canada). Following antigen
retrieval with citrate buffer (pH 6.0), sections were blocked for 1 hour
in 2% BSA. Sections were subsequently incubated with primary anti-
bodies. The primary antibodies were anti–phosphohistone H3 (PH3;
Millipore, Billerica, MA; #06-570; 1:500 dilution), anti–cyclin B1
(Abcam, Cambridge, MA; #ab72, 1:400 dilution), anti–HK-II (Cell
Signaling Technology, Danvers, MA; #2867, 1:100 dilution), and
anti–carbonic anhydrase IX (CAIX; Novus Biologicals, Littleton, CO;
#NB100-417, 1:500 dilution). This was followed by incubation with
HRP polymer conjugate and subsequently with DAB chromogen
(SuperPicture Kit; Invitrogen, Camarillo, CA; #87-8963). The sections
were counterstained with hematoxylin. Immunohistochemistry for
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Ki67 and Glut-1 was performed in the Ventana Benchmark Ultra au-
tomated machine. The primary antibodies were anti-Ki67 (Ventana,
Tuczon, AZ; #790-4286, 16-minute incubation at 37°C) and anti–
Glut-1 (Spring Biosciences, Fremont, CA; #E2840; 1:500 dilution,
24-minute incubation at 37°C). Mounted slides were examined in an
Olympus UTV1-X microscope and images were captured with a
QImaging Retiga 2000R camera.
Frozen sections were fixed with 4% paraformaldehyde and per-
meabilized with 0.05% Triton X-100. After blocking with 5%
BSA in PBS for 1 hour, the sections were incubated overnight with
primary antibodies: rabbit polyclonal anti-CD31 antibody (Abcam;
ab28364, 1:50 dilution) or rabbit anti–cleaved caspase-3 antibody
(Cell Signaling Technology; 9711s; 1:400) and hypoxia inducible
factor-1α (HIF-1α; BD Transduction Laboratory, San Jose, CA), and
fluorescein isothiocyanate–conjugated α–smooth muscle actin (SMA;
Sigma, St Louis, MO; F3777, 1:500]. The sections were then incu-
bated with secondary antibodies conjugated with Alexa Fluor 488 or
Alexa Fluor 594 for 1 hour. Following washing, sections were incu-
bated with 4′,6-diamidino-2-phenylindole (DAPI) and the slides were
mounted with Vectashield mounting medium (H1000). The examina-
tion of tissue sections were done under a Nikon ECLIPSE Ti series
fluorescence microscope, using NIS Elements (BR 3.10) software.
Western Blot
Frozen tissue portions were put in ice-cold lysis buffer and
homogenized. The proteins were resolved by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and then transferred onto poly-
vinylidene difluoride (PVDF) membrane. After blocking for 1 hour
with 5% milk in 0.1% Tween 20 in TBS, the membrane was
incubated overnight with primary antibodies for HIF-1α (BD
Transduction Laboratory; 610958, 1:1000), VEGF (Santa Cruz
Biotechnology, Dallas, TX; SC-152, 1:500), and β-actin (Abcam;
ab8226, 1:10,000). The membranes were subsequently washed with
0.1% Tween 20 in TBS and incubated with the HRP-conjugated
anti-rabbit or anti-mouse secondary (1:10,000) antibodies for 1 hour.
The bands were detected by chemiluminescence using Amersham’s
ECL Plus Western Blot Detection System.
Real-time Polymerase Chain Reaction
Total RNA was extracted from tumor samples using TRIzol reagent
(#15596-026; Invitrogen/Life Technologies, Carlsbad, CA) according
to the manufacturer’s instructions. RNA quality and quantity were
determined by gel electrophoresis and spectrophotometry, respectively.
Genomic DNA contamination was removed with Deoxyribonuclease I
Amplification Grade (#18068-015; Invitrogen/Life Technologies).
Synthesis of cDNA was performed using 1 μg of total RNA accord-
ing to the manufacturer’s protocol of ImProm-II Reverse Transcrip-
tion System (#A3800; Promega, Madison, WI). The primers for
PDGF-C and the endogenous gene β-actin (ACTB) were designed
using Primer Express (3.0) Software from Applied Biosystems (Foster
City, CA), taking care that the forward and reverse sequences were in
different exons. The sequences of primers for PDGF-C are 5′-GGG
CTT GAA GAC CCA GAA GAT-3′ (forward) and 5′-CCA TCA
CTG GGT TCC TCA ACT T-3′ (reverse) and those for ACTB are
5′-AAGGCCAACCGCGAGAAG-3′ (forward) and 5′-ACAGCCTG-
GATAGCAACGTACA-3′ (reverse). Expression levels of PDGF-C
was determined by quantitative real-time polymerase chain reaction
(PCR). This analysis was performed in a thermocycler Applied Biosys-
tems Prism 7500 Sequence Detection System (PE Applied Biosystems,
Inc, Foster City, CA) using relative quantification. The reaction mix-
ture combined 6 μl of SYBR Green PCR Master Mix (#4309155;
Applied Biosystems/Life Technologies, Foster City, CA), 3 μl of
sense/antisense primers, and 3 μl of cDNA. The cycling conditions
were given as follows: 95°C for 10 minutes, 40 cycles of 95°C for
15 seconds, and 60°C for 1 minute. Reactions were done in triplicate.
For each sequence, a standard curve was constructed to determine the
sensitivity and efficiency assays. For each sample, the cycle threshold
(C t) was determined (mean of the three reactions) for both the target
gene and the endogenous control gene and was normalized for cDNA
quantity. Subtracting the C t of the endogenous control gene from the
C t of the target gene yields the ΔC t. The ΔC t of the control reference
was then subtracted from the ΔC t of the tumor sample, yielding the
ΔΔC t, and the relative quantification value was expressed as 2
−ΔΔCt.
Statistics
Statistical significance for the difference of mean values for any
markers between two treatment groups was assessed by two-tailed t test
using Graphpad Prism 5.2. For comparing the levels of markers in
immunohistochemistry and immunofluorescence experiments, mean
pixels indicate the mean readings of four xenografts in each group.
Results
Treatment with TP and PZ
The treatments were started 2 weeks after the subcutaneous injec-
tion of tumor cells, when the majority of tumors were 0.5 cm (size
range of 0.4-0.7 cm). End points for control, PZ, and TP group tumors
were reached after 23, 28, and 46 days (Figure 1), respectively, and
tumors were harvested at these times. For TP + PZ, tumor growth
was inhibited and remained unchanged until ∼50 days, after which
they started growing gradually. However, the tumors in TP + PZ–
treated animals did not reach the end point until 80 days. Therefore,
we were able to examine the effect of continuous treatment with TP +
PZ for 28, 56, and 80 days. When the end points were reached or
at day 80 (for TP + PZ), the coefficients of variation of tumor sizes
Figure 1. Effect of treatment on tumor growth and survival. The
graph represents the effect of treatments on the tumor growth rate.
TP + PZ–treated animals did not reach the end point. In the other
three groups, all the animals belonging to each group were sacri-
ficed when at least one animal in that group reached the end point.
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for control, PZ, TP, and TP + PZ were 0.193, 0.277, 0.049, and
0.301, respectively.
The Effect of Treatments on the Apoptosis, Tumor Hypoxia,
and Angiogenic Gene Expression
Immunofluorescence labeling for cleaved caspase-3 (marker of
apoptosis) revealed that TP + PZ–treated tumors, at all the three
durations, had significantly increased numbers of cleaved caspase-3–
positive cells relative to single agents alone (Figure 2). The apopto-
tic cells were evenly distributed throughout the tumor section rather
than being confined to particular areas. Hypoxia marker CAIX [31]
showed intensely stained areas for CAIX, observed in the tumors
treated with TP for 28 days and those treated with TP + PZ at all
three durations (Figure 3A). Western blot analysis for HIF-1α re-
vealed intense bands in all treatment groups except for untreated
animals and TP-treated animals sacrificed after 46 days of treatment
(Figure 3B). The tumors treated with TP + PZ for 56 and 80 days
showed the highest expression of HIF-1α and VEGF (Figure 3A).
Real-time PCR revealed that the PDGF-C expression was higher in
all the treatment groups, at all durations, compared to the untreated
control (Figure 3C ). It was highest in the later durations (56 and
80 days) of TP + PZ therapy than in other treatment groups. These
results highlighted a strong effect of treatment-induced hypoxia likely
correlating with an antiangiogenic effect.
The Effect of Treatments on Tumor Vessel Density and
Pericyte Coverage
Given the above observations, we next examined the vasculariza-
tion of these tumors. The markers for endothelial cells and pericytes
are CD31 and α-SMA, respectively. Immunofluorescence staining
revealed that, compared to the control, none of the single agents
at any of the durations reduced the microvessel density, whereas
TP + PZ significantly reduced microvessel densities at all the three
durations (Figure 4, A and B). SMA expression increased with time
in the TP + PZ group. The mean ratio of SMA to CD31-positive
areas was used to compare the extent of pericytic coverage of tumor
vasculature (Figure 4C ). This ratio was significantly higher and
≥1.0 in tumors treated with TP + PZ for 56 and 80 days, while
significantly lower in tumors treated with TP + PZ for 28 days,
compared to the control tumors. The SMA/CD31 ratio did not
vary significantly from control in any of the single agent–treated
groups. Control tumors showed both mature blood vessels charac-
terized by larger diameter and thick pericyte coverage (left) and
immature blood vessels characterized by smaller diameter and fewer
pericyte coverage (right). Although the TP + PZ–treated tumors
had higher pericyte coverage, vessels here were smaller than the
mature vessels in control tumors. These observations suggested a loss
of tumor vascularization but maturation of the remaining few vessels
in the TP + PZ tumors.
Figure 2. Apoptosis in the tumor tissue after treatment. Microscopic images (magnification, ×20) of tumor sections showing hypoxic
areas (HIF-1α positive, green) and cleaved caspase-3 (red). The graph below represents the pixels of caspase-3–stained areas, as
measured by ImageJ software.
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The Effect of Treatments on Proliferative Index and Mitotic
Index of Tumor Cells
The observation that tumor growth was significantly reduced by TP
and PZ treatments led us to examine the proliferative and mitotic
indices. The number of proliferating cells, as indicated by Ki67 staining,
was significantly higher in TP (28 days; P = .0009) and TP + PZ
(28 days; P = .0007) groups relative to the control (Figure 5A).
However, in all other groups, it did not show a significant difference
over control tumors. These contrary results, i.e., stable tumor but
with a high proliferative index, indicated a possible cell cycle arrest.
Figure 3. Hypoxia and angiogenic gene expression in tumors after treatment. (A) Microscopic images (magnification, ×40) of tumor
sections on which immunohistochemistry for CAIX were performed. (B) Comparison of expression of HIF-1α and VEGF in various treat-
ment groups by Western blot. The band density ratio, which is used as a parameter for comparison of HIF-1α and VEGF expression in
the histogram (right), indicates the ratio of band density of HIF-1α or VEGF to that of internal control of that sample. The band density
was measured by AlphaEaseFC software. (C) The relative gene expression of PDGF-C with respect to control tumors by 2−ΔΔCt method.
The value represents the statistical significance of difference between PDGF-C gene expression in control groups and the mean gene
expression in all treatment groups combined. TP + PZ (28 days) was not included because this sample demonstrated RNA degradation
(absence of bands for subunits 18 and 28S of RNA by electrophoresis of agarose gel) due to which the C t value for ACTB gene (endogenous
gene used in this methodology) was extremely high.
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Therefore, mitotic index of the tumors were measured by PH3
immunohistochemistry. However, compared to control tumors, the
mitotic index was significantly higher in TP (28 days; P = .005),
TP + PZ (28 days; P = .0002), and TP + PZ (80 days; P = .01)
treatment groups (Figure 5B).
Effect of Treatments on Glut-1 and HK-II Expression
(Indicators of Elevated Glycolysis) by the Tumor Cells
To decipher what could be happening in the tumors as vasculariza-
tion decreased and remaining vessels stabilized, yet with a more hypoxic
microenvironment, we examined other hypoxia and metabolic rele-
vant markers [32]. Immunohistochemistry revealed that expression
of Glut-1 and HK-II were significantly higher in the tumors treated
with TP + PZ for all three durations, compared to control (Figure 6).
In control and single agent–treated tumors, the cells overexpressing
Glut-1 were scattered uniformly among those lacking Glut-1 expression.
In contrast, in TP + PZ–treated tumors, cells overexpressing Glut-1 were
present in groups, separated from those lacking Glut-1 expression.
Discussion
Unlike conventional chemotherapy and therapies that directly tar-
geted tumor cells, antiangiogenic therapy was expected to sustain the
antitumor effect because the expected target was genetically stable
endothelial cells. However, even antiangiogenic therapy was found
to lose efficacy after an initial phase of tumor regression or stabiliza-
tion. In these cases, resistance mechanisms such as up-regulation
of angiogenic factors, vascular maturation, hypoxic adaptation of
tumor cells, and enhanced metastatic potential of tumor cells have
been reported [33–35]. The molecular evolution of resistant cells
Figure 4. The effect of treatments on tumor vasculature. (Top) Microscopic images (magnification, ×20) of tumor sections showing
CD31-positive tumor vasculature (red) and SMA-positive pericytes (green). The two images for control sections indicate the tumor vas-
culature with a high pericyte coverage (left) and those with low pericyte coverage (right). (Bottom left) The comparison of microvessel
densities, measured in terms of pixels of CD31-positive areas in different groups of mice. (Bottom right) The comparison of extent of
pericyte coverage, measured in terms of pixel ratio for SMA to CD31-positive areas in different groups of mice. The pixels were mea-
sured by ImageJ software.
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has been studied by proteomic analysis in response to metronomic
cyclophosphamide in prostate cancer xenografts, revealing the up-
regulation of procoagulant genes and genes conferring reduced depen-
dence on vasculature [36,37]. Conversely, LDM chemotherapy is
reported to induce chemosensitivity to endothelial cells as opposed
to maximum tolerated dose (MTD), which induces cross-resistance
[38]. The residual stem cell population has been reported to be respon-
sible for relapse after metronomic cyclophosphamide in hepatocellular
carcinoma xenografts [39]. Prostate cancer cells that acquired resistance
to in vivo LDM cyclophosphamide has been found to be sensitive to
MTD regimen [40].
In our previous preclinical experiments involving LDM topotecan
and pazopanib in neuroblastoma, prolonged treatment delayed tumor
growth but was unable to stop tumor growth in a neuroblastoma
metastatic model [24]. In the present study, we used MYCN-amplified
SK-N-BE(2) cell line because MYCN amplification is associated with
therapeutic resistance and worse prognosis [41]. Furthermore, as per
our experience, SK-N-BE(2) cell line demonstrates uniform growth
in experimental mice. Here, the immunofluorescence labeling of the
xenografts revealed that tumors treated with TP + PZ maintained a
significantly higher level of hypoxia and higher number of apoptotic
cells at all the three durations. However, the existing vasculature now
exhibited a rich pericyte coverage compared to the control-treated
tumors. The cells in tumors treated with TP + PZ for prolonged
durations (56 and 80 days) demonstrated comparable or significantly
higher proliferative and mitotic indices to that of untreated tumors.
However, unlike untreated tumors and other treatment groups, tumors
in these 56 and 80 days TP + PZ treatment groups had higher levels
of Glut-1 and HK-II, indicative of an adaptation to hypoxia, which
could facilitate survival and proliferation under hypoxia.
In the present study, tumor vessel densities in tumors treated with
single agents were not significantly different from the control when
Figure 5. The effect of treatments on proliferation and mitotic index of tumors. Immunohistochemistry on paraffin-embedded tumor
sections stained with antibodies for (A) proliferation marker Ki67 (magnification, ×20) and (B) mitotic marker PH3 (magnification, ×40).
The brown areas indicate cells or areas expressing Ki67 or PH3. Tonsil was used as positive control for both Ki67 and PH3. The graphs
below the images represent the comparison of proliferative and mitotic indices measured as the pixels for areas positive for Ki67 and
PH3, respectively.
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they reached the end point. Hence, the loss of efficacy of single agent
LDM topotecan and pazopanib can be attributed to the fact that
single agents are unable to sustain antiangiogenic effect. Here, angio-
genesis may occur due to the expression of factors including VEGF
and PDGF-C. In contrast, the tumors in the combination group
maintained a low microvessel density even after 56 and 80 days of
treatment, the stages when they were growing gradually, despite having
higher expressions of VEGF and PDGF-C. Notably, these tumors
had higher expression of hypoxia markers HIF-1α and CAIX. Hence,
tumors can still acquire resistance by mechanisms other than vascular
regrowth. HIF-1α, inducible by hypoxia, is a major cause of anti-
angiogenic resistance [42]. Our result that TP + PZ upregulates
HIF-1α, conflicts with previous reports, where topotecan has been
reported to block HIF-1α and reduce VEGF expression in neuro-
blastoma [43,44]. In addition, combining bevacizumab or sunitinib
with low-dose topotecan reduced downstream targets of HIF-1α such
as VEGF and Glut-3, simultaneously maintaining a low vessel density
in neuroblastoma xenografts [11]. However, in that study, the animals
were treated with the combination for only 2 weeks, whereas in our
study the earliest sacrifice of animals treated with LDM topotecan
and combination was done after 4 weeks (28 days), during which
time the tumor phenotype might change. Prolonged observation may
be key to revealing phenotypic changes that are informative about the
malignant potential.
Figure 6. The effect of treatments on markers of aerobic glycolysis. (A) The microscopic images (magnification, ×20) of tissue sections
stained for antibody for Glut-1. Placenta was used as positive control tissue. (B) The microscopic images (magnification, ×40) of tissue
sections stained with antibody for HK-II. Paraffin-embedded section of a human glioblastoma was used as a positive control. Arrows
indicate the cells expressing Glut-1 or HK-II. The histograms below represent the comparison of pixels for Glut-1– or HK-II–stained areas.
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We entertained the idea that a cause of resistance to the combination
therapy could be higher pericyte coverage. Though, in single agent
groups, there were pericytes around blood vessels, in the TP + PZ groups
treated for 56 and 80 days this fraction was ≥1, indicating that, despite
loss of vascularization, all the existing vasculature had pericyte coverage.
Tumor vascular maturation characterized by increased pericyte coverage
of endothelium is reported to render endothelial cells resistant to apopto-
tic effects of antiangiogenic therapy [33,34]. PDGF-B and PDGF-Chave
been implicated in causing vascular maturation [45,46]. PDGF-C has
been linked to higher pericyte coverage in glioblastoma. Therefore, our
observation of higher PDGF-C expression suggests that PDGF-C may
have contributed to the vascular maturation of TP + PZ–treated tumors.
Next, we considered the various mechanisms by which tumors
treated with TP + PZ for 56 and 80 days might grow despite the
low vasculature and higher hypoxia. This can occur either because
of lower apoptosis or higher proliferation rate compared to TP +
PZ tumors treated for 28 days. We observed that, although the
TP + PZ–treated tumors at all three durations contained a signifi-
cantly higher number of apoptotic cells, these tumors also had an
appreciably higher proliferative index comparable to untreated
and single agent–treated tumors. Here, we conclude that although
some tumor cells succumbed to antiangiogenic therapy, others had
adapted to the hypoxic environment. In stable tumors, the number
of apoptotic cells is balanced by proliferating cells. However, in resis-
tant tumors, though the apoptotic cells are significantly higher than
those in control group, proliferating cells outnumber these apoptotic
cells Another conflicting observation is that tumors treated with TP +
PZ for 28 days had a higher proliferative index than any other
groups. Considering the stable tumor sizes at this stage of therapy,
these tumors would be expected to have relatively lower proliferative
indices. Hence, we postulated that this could be an indication of cell
cycle arrest. There are reports that cell cycle arrest by therapeutic
agents is characterized by dephosphorylation of histone H3, except
for the arrest in mitotic phase [47,48]. In our study, however, sig-
nificantly higher levels of PH3 were observed in TP + PZ–treated
tumors after 28 days of treatment, indicating that the number of cells
reaching M phase is higher in this group. This then is an indication of
a higher proliferative index unless it is mitotic arrest. However, all
the reports of hypoxia-induced cell cycle arrest suggests that hypoxia
causes cell cycle arrest of cancer cells in G1 or G2/M phase [49–51].
There are no reports of hypoxia causing cell cycle arrest in mitotic
phase alone. In addition, if direct cytotoxic effect of topotecan on
tumor cells is considered, it causes cell cycle arrest before the cells reach
mitosis [52]. Therefore, we surmised that the higher Ki67 expression
in tumors treated with TP + PZ for 28 days might have indicated a
higher proliferative index in this group. On another point, although
this could appear improbable, considering the low tumor sizes at
this stage of treatment, the possibility is that TP + PZ therapy demon-
strated a sustained antiangiogenic efficacy until 80 days. The overall
antitumor efficacy achieved by targeting cellular, angiogenic, or
immune parameters was lost before 28 days as the tumor cells started
to proliferate. Because we do not have TP + PZ tumors collected
before 28 days, the actual time limit when TP + PZ therapy could
inhibit the proliferation of tumor cells cannot be established by this
study. Identifying the actual time of tumor dormancy, i.e., before
the tumor cells start proliferating, can be useful in re-inducing tumor
dormancy by modifying the therapy at that point.
Our next query was how tumor cells could proliferate in an environ-
ment characterized by hypoxia and low vasculature as in the TP + PZ–
treated tumors. We postulated that the SK-N-BE(2) tumor xenografts
treated with TP + PZ for prolonged durations (56 and 80 days), being
comprised of heterogeneous population of cells, included some that
were undergoing higher apoptosis and others that had acquired the
potential to survive and proliferate under hypoxia. One mechanism
by which tumor cells acquire the ability to survive and proliferate
under hypoxia is by acquiring dependency on glycolysis, commonly
known as the Warburg effect [53,54]. HIF-1α is known to induce
the Warburg effect in cancers. Combinatorial effects of MYCN and
HIF-1α are reported to promote the proliferation and expression of
Glut-1 and HK-II in MYCN-amplified neuroblastoma cells [55].
Glut-1 and HK-II have been used previously as markers of elevated
glycolysis [32]. In the Warburg metabolic situation, hypoxic cells
compensate for this low output of ATP by increasing the availability
of glucose molecules for cellular functions, especially production of
metabolites needed for growth. This is where Glut-1, the glucose trans-
porter, plays the pivotal role. Glut-1 is upregulated to facilitate the
transport of glucose molecules. Glut-1 up-regulation is associated with
an increased proliferation and worse prognosis in neuroblastoma and
breast cancers [56,57]. Glut-1 has been proposed to be a marker for
hypoxia in solid tumors [31,53,58,59]. Hexokinases are another class
of enzymes that catalyze the first step in glycolysis, i.e., phosphorylation
of glucose. HK-II is upregulated in cancers to facilitate enhanced
glycolysis; therefore, it has been used as a definitive marker of the
Warburg effect in many cancers, including neuroblastoma [55,60].
Down-regulation of HK-II in medulloblastoma tumor cells has ham-
pered aerobic glycolysis and reduced the tumorigenic potential in a
mouse model [61]. Apart from its role in aerobic glycolysis, HK-II also
imparts resistance to chemotherapy-induced apoptosis by binding
to the mitochondrial membrane, thereby reducing its permeability
[60]. Not surprisingly, clotrimazole, which displaces HK-II from mito-
chondria, enhances the cytotoxicity of cisplatin in ovarian cancer [62].
The above evidence led us to perform immunohistochemistry for
Glut-1 and HK-II in our tumor xenografts. Whereas the control and
single agent groups revealed few cells with high Glut-1 expression
uniformly scattered within the tumor, TP + PZ–treated tumors had
cells showing intense staining for Glut-1 present as clusters. HK-II
was also highly expressed in TP + PZ–treated tumors. This indicates
that, in this study, TP + PZ–treated tumors become dependent on
the glycolytic pathway to meet the energy requirement. We therefore
surmise that the hypoxia-challenged tumor cells upregulated HIF-1α
that then led to up-regulation of Glut-1 and HK-II, which were needed
for resumption of strong tumor growth. Interestingly, we observed
foci of such cells suggesting a possible clonogenic effect, that is,
outgrowth of hypoxia-resistant clones.
In summary, we report that LDM topotecan and pazopanib, even if
used in combination, loses antitumor efficacy after some time. This
mechanism of resistance to the combination therapy is different from
that to single agent therapy. Whereas the tumors evade antiangiogenic
effect of single agent therapy, the combination of these agents demon-
strated sustained antiangiogenic effect. The tumors treated with TP +
PZ for prolonged duration have a limited but more mature vasculature.
Despite sustained antiangiogenic effect, overall antitumor efficacy of
TP + PZ is lost because some of the tumor cells acquire capacity
to survive and proliferate under antiangiogenesis-induced hypoxia.
This in turn drives the glycolytic pathway required for maintenance
of tumor growth as revealed by higher staining of Glut-1 and HK-II
in TP + PZ–treated tumors. Interestingly, our time study reveals that
the tumor cells acquire this capacity long before the tumors start to
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show resumption of growth. From a clinical perspective, any sign of a
stabilized tumor burden under such treatments should be taken with
caution. Instead, further investigations into markers of antiangiogenic
resistance would enable clinicians to decide the duration after which
the antiangiogenic therapy need to be discontinued or modified.
Elevated plasma levels of proangiogenic factors have been suggested
as marker of antiangiogenic resistance [63]. On the basis of the pres-
ent study, we also suggest that indicators of proliferation, cell cycle,
and elevated glycolysis in circulating tumor cells can be potential bio-
markers of antiangiogenic resistance. Furthermore, the contrary results
between this study and previous short-term studies, with respect
to HIF-1α and downstream targets in neuroblastoma, supports the
need for long-term preclinical investigation of antiangiogenic thera-
pies if they are to be considered as maintenance regimen [11].
In effect, combining antiangiogenic therapies with drugs targeting
tumor metabolism could be a more effective strategy to overcome
antiangiogenic resistance [42].
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